ES2075169T3 - Agentes de union especifica. - Google Patents

Agentes de union especifica.

Info

Publication number
ES2075169T3
ES2075169T3 ES90312407T ES90312407T ES2075169T3 ES 2075169 T3 ES2075169 T3 ES 2075169T3 ES 90312407 T ES90312407 T ES 90312407T ES 90312407 T ES90312407 T ES 90312407T ES 2075169 T3 ES2075169 T3 ES 2075169T3
Authority
ES
Spain
Prior art keywords
human antibody
reshaped
plap
specific union
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90312407T
Other languages
English (en)
Inventor
Martine Elisa Verhoeyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever NV
Original Assignee
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898926045A external-priority patent/GB8926045D0/en
Priority claimed from GB909019552A external-priority patent/GB9019552D0/en
Application filed by Unilever NV filed Critical Unilever NV
Application granted granted Critical
Publication of ES2075169T3 publication Critical patent/ES2075169T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Abstract

ANTICUERPO HUMANO REFORMADO O FRAGMENTO DE ANTICUERPO REFORMADO HUMANO CON UNA ESPECIFIDAD PARA EL FOSFATASO ALCALINO DE PLACENTA HUMANA (PLAP) QUE SE PRODUCE MEDIANTE LA TRANSFERENCIA DE LAS REGIONES QUE DETERMINAN COMPLEMENTARIAMENTE (CDRS) DE UNA CADENA CELULAR DE HIBRIDOMA ANTI-PLAP DE MURINA H17E2 EN UN MARCO DE UNA REGION VARIABLE DE ANTICUERPOS HUMANOS. LA MOLECULA REFORMADA SE PUEDE UTILIZAR EN EL TRATAMIENTO O EL DIAGNOSTICO DEL CANCER.
ES90312407T 1989-11-17 1990-11-14 Agentes de union especifica. Expired - Lifetime ES2075169T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898926045A GB8926045D0 (en) 1989-11-17 1989-11-17 Specific binding agents
GB909019552A GB9019552D0 (en) 1990-09-07 1990-09-07 Specific binding agents

Publications (1)

Publication Number Publication Date
ES2075169T3 true ES2075169T3 (es) 1995-10-01

Family

ID=26296218

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90312407T Expired - Lifetime ES2075169T3 (es) 1989-11-17 1990-11-14 Agentes de union especifica.

Country Status (16)

Country Link
EP (1) EP0429242B1 (es)
JP (1) JPH05501357A (es)
KR (2) KR970007783B1 (es)
AT (1) ATE123815T1 (es)
AU (1) AU652923B2 (es)
BG (1) BG60687B1 (es)
CA (1) CA2066670A1 (es)
DE (1) DE69020112T2 (es)
DK (1) DK0429242T3 (es)
ES (1) ES2075169T3 (es)
FI (1) FI922220A0 (es)
GR (1) GR3017407T3 (es)
HU (1) HUT64600A (es)
NO (2) NO303066B1 (es)
RO (1) RO110262B1 (es)
WO (1) WO1991007500A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
JP5297742B2 (ja) * 2008-09-26 2013-09-25 株式会社青木科学研究所 金型用粉体含有油性潤滑剤、これを用いた静電塗布方法、及び静電塗布装置
JP6983779B2 (ja) * 2015-11-30 2021-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 非常に特異的な腫瘍細胞表面抗原を標的とするヒト抗体を用いた腫瘍特異的ペイロード送達及び免疫活性化
WO2019240934A1 (en) * 2018-06-12 2019-12-19 Promab Biotechnologies, Inc. Plap-car-effector cells
CN116745324A (zh) 2021-01-27 2023-09-12 信达生物制药(苏州)有限公司 针对cd16a的单域抗体及其用途
WO2023064928A2 (en) * 2021-10-14 2023-04-20 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
CN114014933B (zh) * 2021-11-17 2023-05-02 福州迈新生物技术开发有限公司 抗plap蛋白单克隆抗体、细胞系及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product

Also Published As

Publication number Publication date
KR970007782B1 (ko) 1997-05-16
NO921941D0 (no) 1992-05-15
BG60687B1 (bg) 1995-12-29
ATE123815T1 (de) 1995-06-15
FI922220A (fi) 1992-05-15
DE69020112T2 (de) 1995-11-02
NO303066B1 (no) 1998-05-25
DK0429242T3 (da) 1995-10-16
NO921941L (no) 1992-05-15
RO110262B1 (ro) 1995-11-30
DE69020112D1 (de) 1995-07-20
JPH05501357A (ja) 1993-03-18
HUT64600A (en) 1994-01-28
CA2066670A1 (en) 1991-05-18
KR920703837A (ko) 1992-12-18
KR970007783B1 (ko) 1997-05-16
NO980656D0 (no) 1998-02-16
NO980656L (no) 1992-05-15
WO1991007500A1 (en) 1991-05-30
EP0429242A2 (en) 1991-05-29
HU9201619D0 (en) 1992-08-28
EP0429242B1 (en) 1995-06-14
AU652923B2 (en) 1994-09-15
GR3017407T3 (en) 1995-12-31
FI922220A0 (fi) 1992-05-15
EP0429242A3 (en) 1991-06-05
AU6736990A (en) 1991-06-13

Similar Documents

Publication Publication Date Title
ATE233279T1 (de) Spezifisch bindende agentien
ES2075169T3 (es) Agentes de union especifica.
ATE114189T1 (de) Humane-humane hybridomas für neoplasmen.
BR9708910A (pt) Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento
DK153954C (da) Fremgangsmaade til fremstilling af et monoklonalt antistof, hybridomacellelinie til anvendelse ved fremgangsmaaden samt fremgangsmaade til diagnose og diagnostisk praeparat med det fremstillede monoklonale antistof
EP0160250A3 (en) Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
DK153891C (da) Fremgangsmaade til fremstilling af et monoklonalt antistof, hybridomacellelinie til anvendelse ved fremgangsmaaden samt fremgangsmaade til diagnose og diagnostisk praeparat med det fremstillede monoklonale antistof
DK392387D0 (da) Monoklonalt antistrof til diagnostisk anvendelse og fremgangsmaade til fremstilling af et saadan antistof
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
FR2697088B1 (fr) Anticorps monoclonaux pour le diagnostic différentiel de cancers épithéliaux dans des épanchements séreux, hybridomes les secrétant et kit de diagnostic.
EP0453419A3 (en) Use of the sp-2 monoclonal antibody for diagnostics and for monitoring of the hiv infection progress
DK1414859T5 (da) Monoklonale anti-SSRP-1-antistoffer og hybridomer som producerer antistofferne
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.
PT99114A (pt) Processo para a preparacao de anticorpos monoclonais dirigidos contra complexos formados por trombina e inibidores de trombina
DK182188A (da) Humant tumorassocieret antigen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 429242

Country of ref document: ES